Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors-Reference-Cited by-同舟云学术

Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors

Published:2022-09-07 Issue:1 Volume:37 Page:2434-2451
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

Jeong Hee Jin¹²,Lee Hye Lim³⁴,Kim Sung Joon⁵,Jeong Jeong Hyun³,Ji Su Hyun¹⁶,Kim Han Byeol¹⁶,Kang Miso³⁴,Chung Hwan Won⁷,Park Chan Sun⁵,Choo Hyunah³,Yoon Hyo Jae²,Kim Nam-Jung⁴⁸,Lee Duck-Hyung⁶,Lee Sanghee³⁹,Han Seo-Jung¹¹⁰

Affiliation:

1. Chemical & Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea

2. Department of Chemistry, Korea University, Seoul, Republic of Korea

3. Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea

4. Department of Basic Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea

5. TXINNO Bioscience Inc, Yongin-si, Gyeonggi-do, Republic of Korea

6. Department of Chemistry, Sogang University, Seoul, Republic of Korea

7. Computational Science Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea

8. Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, Republic of Korea

9. Department for HY-KIST Bio-convergence, Hanyang University, Seoul, Republic of Korea

10. Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul, Republic of Korea

Funder

Korea Institute of Science and Technology

KIST Institutional Program

National Research Foundation of Korea

National Research Foundation

Ministry of Science and ICT

National Research Council of Science & Technology

Korea governmen

Korea Drug Development Fund

Ministry of Trade, Industry, and Energy

Ministry of Health and Welfare

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14756366.2022.2119566

Reference37 articles.

1. Cancer immunotherapy trials: leading a paradigm shift in drug development

2. Cancer immunotherapy trials: leading a paradigm shift in drug development

3. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

4. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

5. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy;Journal of Medicinal Chemistry;2023-11-14

2. Current Developments of Pyrrolo[2,3-d]pyrimidines with Anticancer Potential (A Review);Russian Journal of General Chemistry;2023-10

3. Studies on the Inhibition of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) by 2-(3,4-Dihydroxyphenyl)-7,8-dihydroxy-3-methoxychromen-4-one, a Flavonoid from Pistacia chinensis;Chemistry;2023-09-30

4. Synthesis, crystal structure, DFT, vibrational properties, Hirshfeld surface and antitumor activity studies of 3-((4-methylpiperazin-1-yl) methyl)-1-octyl-5-(p-tolyl)-1H-pyrrolo[2,3-c]pyridine;Journal of Molecular Structure;2023-09

5. Identification of (−)-Epigallocateshin gallate derivatives promoting innate immune activation via 2′,3′-cyclic GMP-AMP-stimulator of interferon genes pathway;Bioorganic & Medicinal Chemistry Letters;2023-06